Based on the Opus Genetics, Inc. stock forecast from 1 analysts, the average analyst target price for Opus Genetics, Inc. is USD 8.00 over the next 12 months. Opus Genetics, Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Opus Genetics, Inc. is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Opus Genetics, Inc.’s stock price was USD 1.15. Opus Genetics, Inc.’s stock price has changed by -0.86% over the past week, +11.65% over the past month and 0% over the last year.
No recent analyst target price found for Opus Genetics, Inc.
No recent average analyst rating found for Opus Genetics, Inc.
Company Overview Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan. Read Less
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal...Read More
Frequently Asked Questions About Opus Genetics, Inc. (IRD) Stock
Based on ratings from 1 analysts Opus Genetics, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on IRD's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for IRD is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on IRD's stock to indicate if its overvalued.
The last closing price of IRD's stock was USD 1.15.
Unfortunately we do not currently have any market capitalization data for IRD's stock.
Based on targets from 1 analysts, the average taret price for IRD is projected at USD 8.00 over the next 12 months.
This means that IRD's stock price may go up by +595.65% over the next 12 months.
We can't find any ETFs which contains Opus Genetics, Inc.'s stock.
As per our most recent records Opus Genetics, Inc. has 14 Employees.
Opus Genetics, Inc.'s registered address is 37000 Grand River Avenue, Farmington Hills, MI, United States, 48335.
You can get more information about it from Opus Genetics, Inc.'s website at https://opusgtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Opus Genetics, Inc. (IRD) Stock
Based on ratings from 1 analysts Opus Genetics, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on IRD's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for IRD is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on IRD's stock to indicate if its overvalued.
The last closing price of IRD's stock was USD 1.15.
Unfortunately we do not currently have any market capitalization data for IRD's stock.
Based on targets from 1 analysts, the average taret price for IRD is projected at USD 8.00 over the next 12 months.
This means that IRD's stock price may go up by +595.65% over the next 12 months.
We can't find any ETFs which contains Opus Genetics, Inc.'s stock.
As per our most recent records Opus Genetics, Inc. has 14 Employees.
Opus Genetics, Inc.'s registered address is 37000 Grand River Avenue, Farmington Hills, MI, United States, 48335.
You can get more information about it from Opus Genetics, Inc.'s website at https://opusgtx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IRD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
